Redefining Optical In-Vivo Imaging Performance

Redefining Optical In-Vivo Imaging Performance

With the introduction of the dual-use hybrid OI/CT modality, MILabs redefines how researchers’ image in-vivo animals. The optical module can be used on the bench for high throughput planar optical imaging, while deep tissue 3D imaging is made possible by moving the module to MILabs’ ultra-high definition CT or Nuclear/CT platform. For the first time, this enables diagnostic CT level image data to correct optical signals for tissue scatter and absorption variations in tissue, thus enabling quantitative 3D/4D optical tomography reconstruction. For further reading, click here.

On the cover…

Researchers at the Department of Nanomedicine and Theranostics of RWTH Aachen University macroscopically investigated biodistributions and target site accumulation of CCPM (Core-crosslinked polymeric micelles). Fluorophore-labeled CCPM were intravenously injected in mice bearing 4T1 triple-negative breast cancer (TNBC) tumors. Their localization at the whole-body, tissue, and cellular level was analyzed using MILabs non-invasive CT-guided 3D fluorescence tomography (FLT/CT) and 2D fluorescence intensity imaging. For further reading, click here.

As used by leading academic institutions and biopharma companies

Researchers at Columbia University published using MILabs’ CT-guided 3D fluorescence tomography (FLT/CT) for drug development. As illustrated, Cy7 labeled mouse albumin (Cy7-ALB) located at different depths within a mouse brain causes wild image intensity changes with planar IVIS, while 3D tomographic MILabs’ FLT/CT delivers quantitative results and excellent localization. After further comparison of FLT/CT with ⁸⁹Zr PET/CT, they concluded that MILabs’ OI/CT could reliably be used to image glioblastomas. Click here for the publication.

Importance of combining Ultra-high Definition CT with Optical Imaging

High-resolution, low-dose CT imaging is a critical part of MILabs OI/CT Optical Tomography technology. It is essential for correcting optical light scattering and absorption differences, and the diagnostic CT capabilities enable high-resolution angiography of solid tumor growth. Progression to malignancy depends on a complex interaction between tumor cells and the body’s blood vessels. Blood vessels provide the route for delivering most therapeutics with optical reporters to the tumor or oxygen to effectuate therapy. This duality in the tumor microvasculature’s cancer therapy role underscores a dual-modality OI/CT system’s advantages to complement molecular images with intravital images of complex vascular biology. For further reading, click here

International Workshop on Radiobiology of Molecular Radiotherapy

Initially planned in Montpellier in May 2020, the MRT Radiobiology meeting has been converted into a virtual conference on March 17th and 18th, 2021. It’s the first of a series of workshops launched by the European MRT radiobiology working group that will be held in Europe every two years. More information at: https://www.mrtradiobiology.com

Prostate cancer: Lutetium-177 PSMA-SPECT

Eline Ruigrok, et al. of the Erasmus MC, illustrate that the selection of linker composition seems essential in designing novel molecular radiotherapies. A MILabs VECTor/CT system was used for an extensive preclinical evaluation of lutetium-177-labeled PSMA-specific SPECT tracers for prostate cancer radionuclide therapy. For further reading, click here.

MILabs Preclinical Imaging Solutions

Job Openings to support MILabs’ accelerating growth

With a compounded annual growth rate of nearly 50% since 2018, MILabs seeks talented individuals to further scale-up its organization and to strengthen the support of its customers and industry collaborators.

We are searching for:

A Post-Doctoral Fellowship in Nuclear Medical Physics at University of Massachusetts, Worchester, USA.
Pre-clinical X-ray CT Specialist (Ph.D.) at MILabs
Sales & Business Director North America at MILabs
Field Service Engineer North America at MILabs
Production Lead Clinical Systems at MILabs

Our mailing address is:
Duwboot 7a, 3991 CD Houten, The Netherlands

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Meet Us At

23 May

Japanese Society for Molecular Imaging

23 May - 24 May
29 May

The 7th Annual Preclinical Imaging Consortium

29 May - 31 May
6 Jun

Young Research meeting Torino

6 June - 7 June
8 Jun

SNMMI 2024 Toronto

8 June - 11 June
10 Jun

EACR Rotterdam

10 June - 13 June
17 Jun

Congrès RIV 2024 Lyon

17 June - 18 June
19 Jun

Intro > Preclinical Molecular Imaging + Applications Biomedical Research

19 June - 21 June
24 Jun

IQ GLAMS Advanced Molecular Imaging Michigan State University

24 June - 27 June

Redefining Optical In-Vivo Imaging Performance

Meet Us At

Global Sales, Service & Support

Distributors